New cocktail aims to shrink untreatable liver tumors
NCT ID NCT07543783
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of low-dose bevacizumab (a blood vessel growth blocker) and adebrelimab (an immunotherapy) along with two liver-directed procedures (TACE and HAIC) as a first treatment for people with unresectable hepatocellular carcinoma, a type of liver cancer that cannot be surgically removed. The study will enroll 38 participants to see how well the treatment shrinks tumors and delays cancer growth. It is a single-arm trial, meaning everyone gets the same treatment, and there is no comparison group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bevacizumab (low-dose) and adebrelimab (an immunotherapy drug)
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for people with unresectable liver cancer, potentially shrinking tumors and delaying disease progression.
- What could go wrong
- This is a small, early-phase trial (38 participants) with no control group, so results may not be definitive. The combination of drugs and procedures also carries risks of serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADEBRELIMAB (SHR-1316) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple therapy shrink untreatable liver tumors?
- Breath of life: new test could sniff out gut cancers before they spread
- Immune cell therapy takes on untreatable liver cancer
- Could your own immune cells keep liver cancer from coming back?
- New ultrasound technique could reveal hidden blood vessels in liver tumors
- New imaging tracer could spot hidden cancers and fibrosis in one scan